Macroaxis LLC’s Post

Our recent technical analysis of Alzamend Neuro (USA Stocks:ALZN): Alzamend Neuro stock has an average 'Buy' rating from two analysts. This consensus is likely based on technical analysis, a method that uses price momentum, patterns, and trends from historical prices. The goal is to identify signals based on the market sentiment of Alzamend Neuro's investors and their perception of the stock's future value. Let's delve into a few aspects of Alzamend's technical analysis. Main Points Alzamend Neuro (ALZN) exhibits a promising technical outlook, with a potential upside of 11.74% hinting at the stock's potential for significant price appreciation. The stock's Mean Deviation of 4.26 and Standard Deviation of 6.55 indicate a moderate level of price volatility, which could offer lucrative trading opportunities for risk-tolerant investors. However, investors should also consider the company's financial health, as it reported a loss of $14.9M in Net Income from Continuing Operations. The stock's Beta of 0.026 also suggests a low correlation with the broader market, providing a potential hedge against market volatility.Continue To Read... https://lnkd.in/gW-uTCEm

**Why Is Impinj (PI) Stock Rocketing Higher Today?** *Invest in the Future of Healthcare with Impinj Stock! 🚀* Summary: In today's fast-paced world, investing wisely is crucial to securing a healthy future for yourself and your loved ones. As an investment advisor, I am excited to share with you the incredible growth potential of Impinj (PI) stock. By investing in this innovative company, you can not only grow your Health Savings Account (HSA) but also contribute to revolutionizing the healthcare industry. Impinj is a market leader in developing cutting-edge solutions that utilize internet-of-things (IoT) technology to enhance healthcare delivery. Their advanced RFID (Radio-frequency identification) products have significantly improved patient tracking, inventory management, and overall operational efficiency in hospitals and healthcare facilities. The recent surge in Impinj stock can be attributed to its impressive financial performance and groundbreaking technological advancements. Their solutions are solving critical challenges within the healthcare sector, enabling healthcare providers to offer better care and outcomes for patients. As the demand for these innovative technologies continues to rise, Impinj is poised for exponential growth, making it an incredibly attractive investment opportunity. Don't let the fear of missing out hold you back! Invest in Impinj stock today and join the movement towards a healthier future. Take advantage of the benefits of HSA investing while aligning your investments with the wellbeing of your family and the broader healthcare industry. #hsa #investing #healthcare #health #family #wellness 🌱💰 [Call to Action] To learn more about investing in Impinj or expanding your HSA investments, reach out to me today. Let's make the most of this exceptional opportunity and secure a prosperous future together! 💪📈

I own Boston Scientific (ticker = BSX) in my personal investment portfolio. BSX supplies a very wide array of medical devices, many of which support surgical interventions. You can find the full list of products on the company’s website. I think of the BSX product portfolio as offering the benefits of diversification within a single company. The company has very fast-growing revenues and earnings. Over the last three years, BSX has generated annualized revenue and earnings growth of 13% and 103%, respectively. BSX is highly profitable, with a 12% net income margin and 11% free cash flow margin. BSX has a Glassdoor rating of 4.2 out of 5, indicating that its employees are “very satisfied” with their employment with the company. I look at Glassdoor ratings as a proxy measure of management quality. BSX is fairly expensive, with a forward P/E of 28x. However, figuring in expected earnings growth, P/E on 2027 earnings is only 22x. Additionally, the short interest ratio (shorts as % of free float) is only 0.96%, indicating that few short sellers believe that current valuation levels are unsustainable. With respect to share price performance, the stock has returned 40% over the last year, 72% over the last 3 years, and 102% over the last 5 years. Of course, past share price performance is no guarantee of future performance. Medtech stocks such as BSX typically play a defensive role in a portfolio. A fast-growing medtech stock such as BSX should help a portfolio outperform during a market pull-back, especially given its diversified product mix. Of course, these views are my own personal investment opinions. You should do your own research, taking into account your own personal risk-return objectives. Thanks for reading my posts! #BSX #bostonscientific #medtech

This Medical Devices Stock Has Several Catalysts, Says Bullish Analyst https://ift.tt/1m4BakC Teleflex gets an upgraded rating. Analyst Matt O'Brien takes it from Neutral to Overweight, and raises the price target from $205 to $245. Latest Ratings for TFX Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Raymond James Maintains Outperform Feb 2022 Raymond James Maintains Outperform View More Analyst Ratings for TFX View the Latest Analyst Ratings read more via Benzinga - Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals https://ift.tt/vFt8x2m July 01, 2024 at 01:00PM

2024 is likely to see an uptick in M&A, IPO's and continued YOY growth against strong 2023 performances in the Medical Device category. Key trends evolving are the emergence of PFA as a new major technology in the US-EP market and a return to sanity from the GLP-1 inhibitor impact on medical device company valuations

An interesting insight on the long-term growth of the MedTech industry as it relates to the GLP-1s and the short-term growth of the industry as the spin-off's slow: https://lnkd.in/gVahNpJx

'Doing what it says on the tube', was the headline from a Panmure Liberum report in the wake of Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s interim results. In summary, the numbers represented a landmark for management and shareholders as they revealed the group, which has developed a fast-acting erectile dysfunction gel, had hit profitability ahead of schedule. Not only that, Futura's management expects its performance for the year as a whole to be well ahead of current market forecasts. "Futura has delivered a really strong set of interims," said Panmure-Liberum in a note to clients. "All of the key numbers were ahead of expectations and this together with the earlier-than-expected US launch is triggering material upgrades to our forecasts as well as a reduction in forecast risk, with revenue now coming from multiple partners / territories." Its partner in America, the UK-based healthcare giant Haleon, is expected... More at #Proactive #ProactiveInvestors http://ow.ly/MriZ105Ilx4

📊 Quarterly Report Lumos Diagnostics has today released its Quarterly Report & 4C for the period ending 30 September 2024. Key highlights from the Quarter include: 🔹 Unaudited revenue of US$3.4 million for the quarter, up 209% compared to the prior corresponding period (pcp) (Q1 FY24 - US$1.1 million). 🔹 Product revenue was up 200% over Q1 last year and Services revenue was up 210% on the pcp. 🔹 Successfully completed A$10.0 million capital raise, strongly supported by new and existing shareholders, Tenmile and Ryder Capital. 🔹 Cash balance of US$5.7 million as at 30 September 2024, prior to receipt of Retail Offer Proceeds of A$6.9 million. 🔹 Operating cash outflow of US$2.6 million, including cash receipts of US$1.2 million with the next Hologic milestone payment expected in Q2. 🔹 New and expanded FebriDx distributor agreements with leading distributors, Henry Schein and Thermo Fisher  Post reporting date signed partnership agreement with BARDA for US$3.0 million in non-dilutive funding to support FebriDx CLIA waiver trial in the US, with funding options to expand to US$8.3 million. Lumos CEO, Doug Ward noted: “With a strong pipeline of projects and partnerships and balance sheet strength, supported by the recent capital raise, we are well-positioned for continued growth and success.” Read the ASX release 👉 https://lnkd.in/gbqiT_YV $LDX #LDX #Lumos #diagnostics #pointofcare #medtech #healthcare #innovation

"IRME: IR-Med’s Potential for Profitable Growth in Future Years Supports Price Target of $3.00." Great IR-Med analysis by Zacks Investment Research who have reaffirmed their price target of $3.00 per share. ✍️"IR-Med (OTC:IRME) released its 10-Q filing on August 13, 2024 and the results were largely in line with expectations." ✍️"Our primary valuation tool utilizes a Discounted Cash Flow process. Under the scenario described above, our DCF based valuation target is approximately $3.00 per share. Our target price may be conservative as it utilizes a high discount rate of 15%." ✍️"IR-Med has the potential to grow both revenues and earnings at very robust double-digit growth rates starting in 2025 if it is able to execute on the commercialization of its PressureSafe and DiaSafe devices. The company’s current stock price does not likely reflect that potential level of profitable growth in the future, and we believe the stock to be significantly undervalued at this time." Read the full paper here: https://lnkd.in/e777Wuiy

The DNB//Back Bay Partnership’s #MarketUpdate report for the week ending July 26th is now available. Highlights include:    ➡️ Small cap dominated indices outperformed the broader market as the capital rotation out of large caps continues    ⏹️ Biotech public equities directly benefit from this market dynamic, with the NBI rising 2.5% ⏹️ We expect this small cap rotation to continue due to imminent rate cuts and growing concerns about lofty large cap valuations    ➡️ With four rounds raising $100M or more this past week, the #lifescience private markets continue to be highly active, adding to an already strong year to-date     ⏹️ Notably two medical device companies, Imperative Care and Kestra Medical Technologies, Inc., raised >$100M    ➡️ Edwards Lifesciences acquired JenaValve Technology, Inc. and Endotronix for $1.2B, expanding their transcatheter aortic valve replacement business, which generated >$1B in sales in Q1 2024, and remote patient monitoring business    ➡️ Rotech Healthcare, a home medical equipment company focused on providing care for common obesity comorbidities, was acquired by Owens & Minor for $1.4B despite growing competitive pressures from obesity therapeutics    Read the full update here: https://bit.ly/3YkGtPG     #healthcaremarket #investmentbanking #corporatebanking #marketsinc #markettrends #financing #BBLSA #DNB